Bile Acid Metabolism Subtypes and Prognosis Markers in CRC

2026-04-12

Integrative Subtyping by Bile Acid Metabolism Reveals Prognostic Markers in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) represents a leading cause of cancer-related morbidity and mortality worldwide, with over two million new cases annually [source_type: paper][source_link: 10.3389/fonc.2025.1739534]. Despite the transformative impact of immune checkpoint inhibitors (ICIs), primary resistance remains a substantial clinical challenge, and only a subset of CRC patients—often those with microsatellite instability-high (MSI-H) tumors—derive significant benefit. Bile acid metabolism is increasingly recognized for its multifaceted role in CRC pathogenesis, acting beyond its classical function in lipid absorption to influence tumorigenesis, inflammation, and the tumor immune microenvironment (TIME). However, the molecular underpinnings by which bile acid metabolism shapes the TIME and its implications for prognosis and immunotherapy response in CRC have not been systematically characterized.

Key Innovation from the Reference Study

Feng et al. (2026) advance the field by applying an integrative transcriptomic approach to subtype CRC based on bile acid metabolism activity, leading to the identification of three key genes—CLCA1, UGT2A3, and ZG16—as markers linked to immune dysregulation and poor prognosis [source_type: paper][source_link: 10.3389/fonc.2025.1739534]. This is the first large-scale study to leverage bile acid metabolic profiling for molecular stratification in CRC, successfully bridging metabolic phenotypes with immune landscape features and clinical outcomes.

Methods and Experimental Design Insights

The authors utilized The Cancer Genome Atlas-Colon Adenocarcinoma (TCGA-COAD) transcriptome and clinical dataset as their primary discovery cohort. Unsupervised consensus clustering was performed based on bile acid metabolism-related gene expression to define molecular subtypes. These subtypes were analyzed for differences in overall survival (OS), patterns of immune cell infiltration (including CD8+ T cells and M1 macrophages), and global gene expression profiles. Key hub genes were identified through a combination of protein–protein interaction (PPI) network analysis and Cox proportional hazards regression. Findings were validated in both the Gene Expression Omnibus (GEO) CRC cohort and independent clinical samples, ensuring robustness across datasets and patient populations. Survival analyses and correlation with Tumor Immune Dysfunction and Exclusion (TIDE) scores were further performed to assess prognostic and immunological relevance.

Protocol Parameters

assay | RNA-seq (bulk) | 50–100 ng input RNA | global transcriptome profiling in CRC tissues | enables subtype discovery and biomarker identification | source_type: paper
assay | qRT-PCR validation | 1–10 ng input RNA | confirmation of hub gene expression in clinical samples | ensures reproducibility and cross-cohort validation | source_type: paper
assay | TIDE analysis | normalized gene expression data | assessment of immune dysfunction and exclusion | links gene markers to immunotherapy response | source_type: paper
assay | reverse transcription of low-concentration RNA | ≤10 ng input RNA | for rare or low-yield clinical specimens | maximizes detection sensitivity for low-copy genes | workflow_recommendation
assay | genomic DNA contamination removal | prior to RT | prevents false positives in gene expression analysis | critical for accurate quantification in qPCR | workflow_recommendation

Core Findings and Why They Matter

The study stratified CRC patients into bile-low and bile-high subgroups. The bile-low group exhibited significantly worse overall survival (p = 0.0049) [source_type: paper][source_link: 10.3389/fonc.2025.1739534]. Notably, this group also showed increased infiltration of CD8+ T cells (p < 0.05) and M1 macrophages (p < 0.01), suggesting that altered bile acid metabolism may drive immune landscape differences in CRC. Differential expression analysis revealed consistent downregulation of CLCA1, UGT2A3, and ZG16 in tumor tissues (vs. normal) across both TCGA-COAD and GEO cohorts, as well as in independent clinical samples. Of these, high CLCA1 expression was robustly associated with improved overall survival (p < 0.001), positioning it as a promising prognostic biomarker. All three genes were negatively correlated with TIDE scores, indicating potential roles in modulating immune dysfunction and resistance to immunotherapy. These findings underscore the emerging paradigm that metabolic pathway signatures—here, bile acid metabolism—can be harnessed to define clinically relevant CRC subtypes and inform patient stratification for immune-based therapies.

Comparison with Existing Internal Articles

Recent internal resources highlight the technical challenges in gene expression analysis within complex oncology settings, including the need for high-fidelity cDNA synthesis from low-concentration and high-GC content RNA and the importance of genomic DNA contamination removal. For example, the article "HyperScript III RT SuperMix: Enabling High-Fidelity qPCR" explains how next-generation reverse transcriptase formulations address biases and sensitivity issues, particularly relevant when validating low-abundance biomarkers like CLCA1, UGT2A3, or ZG16 [source_type: workflow_recommendation][source_link: https://first-strand-cdna.com/index.php?g=Wap&m=Article&a=detail&id=229]. Similarly, "Redefining Gene Expression Analysis in Translational Oncology" critically reviews the requirements for robust cDNA synthesis in immunogenomic workflows—requirements that directly map onto the study's qRT-PCR validation steps and the need for accurate gene expression quantification in low-yield clinical samples. These articles reinforce that meticulous workflow optimization, including efficient reverse transcription of low-concentration RNA and genomic DNA removal, is essential for reproducible biomarker discovery in CRC.

Limitations and Transferability

While the study's multi-cohort validation enhances generalizability, several limitations should be acknowledged. First, the molecular subtypes and associated hub genes were derived from bulk transcriptomic data, which may not fully capture tumor heterogeneity at the single-cell level. Second, while negative correlations with TIDE scores suggest relevance for immunotherapy responsiveness, prospective clinical trials are warranted to confirm predictive utility. Finally, external datasets beyond GEO and single-center clinical samples would further strengthen the transferability of the findings.

Research Support Resources

For researchers aiming to replicate or extend these workflows, high-efficiency reverse transcription and rigorous genomic DNA removal are critical—especially for gene expression analysis by qPCR in clinical oncology studies. Solutions like HyperScript™ III RT SuperMix for qPCR (with gDNA wiper) (SKU K1585, APExBIO) are designed to support robust cDNA synthesis even from low-concentration or high-GC content RNA, ensuring accurate quantification of targets such as CLCA1, UGT2A3, and ZG16 [source_type: product_spec][source_link: https://www.apexbt.com/hyperscripttm-iii-rt-supermix-for-qpcr-with-gdna-wiper.html]. This reagent integrates an optimized gDNA wiper step, streamlining workflow and minimizing contamination risks in two-step qRT-PCR assays. Adopting such validated tools can help researchers achieve reproducible results in biomarker discovery and translational CRC research.